Filing Details

Accession Number:
0001209191-20-001755
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-06 16:15:15
Reporting Period:
2020-01-02
Accepted Time:
2020-01-06 16:15:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1654151 Deciphera Pharmaceuticals Inc. DCPH Pharmaceutical Preparations (2834) 200299725
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1715153 Arthur James Bristol C/O Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham MA 02451
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-02 15,553 $1.89 15,553 No 4 M Direct
Common Stock Disposition 2020-01-02 9,541 $57.51 6,012 No 4 S Direct
Common Stock Disposition 2020-01-02 5,347 $58.08 665 No 4 S Direct
Common Stock Disposition 2020-01-02 365 $59.38 300 No 4 S Direct
Common Stock Disposition 2020-01-02 300 $61.87 0 No 4 S Direct
Common Stock Acquisiton 2020-01-03 7,989 $1.89 7,989 No 4 M Direct
Common Stock Disposition 2020-01-03 729 $55.96 7,260 No 4 S Direct
Common Stock Disposition 2020-01-03 5,250 $57.21 2,010 No 4 S Direct
Common Stock Disposition 2020-01-03 1,810 $58.17 200 No 4 S Direct
Common Stock Disposition 2020-01-03 200 $58.72 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-01-02 15,553 $0.00 15,553 $1.89
Common Stock Stock Option (Right to Buy) Disposition 2020-01-03 7,989 $0.00 7,989 $1.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
47,855 2025-12-17 No 4 M Direct
39,866 2025-12-17 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.87 to $57.86, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.87 to $58.73, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.17 to $59.56, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.68 to $62.25, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.55 to $56.38, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.57, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.66 to $58.65, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 to $58.75, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  10. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.